Answers are grounded in this paper and cite their sources.
Lyme borreliosis (LB) is an emerging tick-borne zoonosis in Europe, transmitted primarily by Ixodes ricinus and Ixodes persulcatus. The causative agent, Borrelia burgdorferi sensu lato (s.l.), comprises approximately 20 genospecies, of which five are responsible for human infection in Europe: Borrelia afzelii, Borrelia garinii, B. burgdorferi sensu stricto (s.s.), Borrelia bavariensis, and Borrelia spielmanii. Due to limitations in direct pathogen detection, LB diagnosis relies mainly on serological assays. However, cross-reactive antibodies can compromise both specificity and sensitivity, highlighting the need for more specific antigenic targets and improved diagnostic strategies beyond conventional two-tier approaches. Epitope mapping represents a promising strategy to identify highly specific immunoreactive regions and reduce cross-reactivity. In this study, we identified immunoreactive peptides to improve LB serodiagnosis. Linear B-cell epitopes were mapped using peptide microarrays across three major European genospecies (B. afzelii, B. burgdorferi s.s., and B. garinii), revealing regions reactive to IgG, IgM, or both. Selected IgG peptides showed sensitivities of 81.6–92.1% and specificities of 92.1–94.7%, whereas IgM peptides exhibited sensitivities of 77.8–94.4% and specificities of 94.6–97.3%. A chimeric protein designed for IgG detection achieved a sensitivity of 94.7% and a specificity of 97.4%. These findings demonstrate that epitope-based antigen design and chimeric constructs can enhance the accuracy of LB serodiagnosis.
No takes yet. Share an insight, caveat, or question.
Moraga‐Fernández et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: